Applied Therapeutics’ New Drug Application (NDA) for govorestat, a potential treatment for Classic Galactosemia, was rejected by the FDA. While the reasons remain unclear, this unexpected setback significantly impacts APLT stock and the future of the drug. However, the company’s ongoing SORD program remains unaffected and offers a potential path to future revenue.